CD274 and neoplasm: The non-overlapping mechanisms of PD-L1 and VISTA make this combination an ideal strategy to overcome immune suppression, as shown in preclinical models where dual blockade had synergistic activity against T-cells favoring anti-tumor responses [124,132].